Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.48 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3533290 | 0.84 | CYP1A2 (0.62) | KDM4ECYP1A2ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL27727433 | 0.83 | CYP1A2 (0.57) | KDM4ECYP1A2ALDH1A1SMN1; SMN2CYSLTR1 | |
| SCHEMBL8648449 | 0.82 | FFAR1 (0.76) | CYSLTR1FFAR1AKR1B1CYSLTR2 | |
| SCHEMBL547194 | 0.80 | FFAR1 (0.63) | KDM4ECYP1A2CYSLTR1FFAR1AKR1B1 | |
| SCHEMBL8650861 | 0.80 | CYSLTR1 (0.57) | CYP1A2CYSLTR1FFAR1AKR1B1CYSLTR2 | |
| SCHEMBL9042289 | 0.80 | PDE10A (0.59) | KDM4ECYP1A2ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3588078 | 0.79 | HDAC1 (0.66) | CYP1A2SMN1; SMN2 | |
| SCHEMBL27700541 | 0.79 | CYP1A2 (0.51) | KDM4ECYP1A2ALDH1A1SMN1; SMN2CYSLTR1 | |
| SCHEMBL27406008 | 0.78 | SUCNR1 (0.50) | KDM4E | |
| SCHEMBL2854918 | 0.78 | KDM4E (0.45) | KDM4ECYP1A2ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
| US-9834564-B2 | Substituted quinolines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834564-B2 | Substituted quinolines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20150166571-A1 | Heteroaryl Compounds and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166571-A1 | Heteroaryl Compounds and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-06-18 | — | — | US | disclosed |
| US-8969349-B2 | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969349-B2 | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2011150156-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-7652036-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-7652036-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-7652036-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-20060079528-A1 | (E)-3-(1,3-Benzoxazol-2-yl)-N-hydroxy-2-propenamide; Methyl (E)-3-(2-quinolinyl)-2-propenoate; histone deacetylase inhibitors; inflammatory disease; cancer | TOPOTARGET UK LIMITED (GB) | 2006-04-13 | — | — | US | disclosed |
| EP-1599449-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TopoTarget UK Limited (GB) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076386-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | PDE10A, PDE2A, PDE3A | KDM4E 202/4885CYP1A2 220/4885ALDH1A1 559/4885 |
| US-20060079528-A1 | (E)-3-(1,3-Benzoxazol-2-yl)-N-hydroxy-2-propenamide; Methyl (E)-3-(2-quinolinyl)-2-propenoate; histone deacetylase inhibitors; inflammatory disease; cancer | HDAC1, HDAC11, HDAC5 | KDM4E 35/4885CYP1A2 2188/4885ALDH1A1 1467/4885 |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | KDM4E 969/4885CYP1A2 80/4885ALDH1A1 560/4885 |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | PDE4A, PDE2A, PDE9A | KDM4E 1397/4885CYP1A2 751/4885ALDH1A1 1140/4885 |
| US-20150166571-A1 | Heteroaryl Compounds and Methods of Use Thereof | COMT, GPR119, NLN | KDM4E 969/4885CYP1A2 80/4885ALDH1A1 560/4885 |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | HDAC1, HDAC7, HDAC5 | KDM4E 72/4885CYP1A2 1355/4885ALDH1A1 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.